The PROTACtable genome

3d

The PROTACtable genome

Nature Reviews Drug Discovery, Published online: 20 July 2021; doi:10.1038/s41573-021-00245-xTargeted protein degradation by proteolysis-targeting chimeras (PROTACs) is attracting substantial interest as a therapeutic modality that could circumvent some limitations of traditional small-molecule drugs. This article presents a systematic approach to assessing...

3d

Small activating RNAs lead the charge to turn up gene expression

Nature Reviews Drug Discovery, Published online: 15 July 2021; doi:10.1038/d41573-021-00127-2As small activating RNAs gear up to enter phase II testing, other noncoding RNAs that upregulate gene expression are also progressing towards the clinic. But it’s early days for a complex field.

2w

Small activating RNAs lead the charge to turn up gene expression

2w

FDA new drug approvals in Q2 2021

Nature Reviews Drug Discovery, Published online: 15 July 2021; doi:10.1038/d41573-021-00126-3FDA new drug approvals in Q2 2021

2w

FDA new drug approvals in Q2 2021

2w

Can a platform of platform companies open up more opportunities?

Nature Reviews Drug Discovery, Published online: 14 July 2021; doi:10.1038/d41573-021-00125-4Luisa Salter-Cid, the Chief Scientific Officer of Pioneering Medicines, will build a portfolio of programmes by tapping technologies on offer at dozens of companies founded by venture capital firm Flagship.

2w

Can a platform of platform companies open up more opportunities?

2w

The glomerular filtration barrier: a structural target for novel kidney therapies

Nature Reviews Drug Discovery, Published online: 14 July 2021; doi:10.1038/s41573-021-00242-0Numerous kidney diseases are characterized by a breakdown of the glomerular filtration barrier, which forms the interface between the blood and urine. In this Review, Daehn and Duffield discuss strategies to target components of this barrier, focusing on mechanisms...

2w

The glomerular filtration barrier: a structural target for novel kidney therapies

2w